Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects,
Omar Castaneda Puglianini1,2, Deniz Peker3, Linsheng Zhang3
1H. Lee Moffitt Cancer Center & Research Institute, Department of Blood & Marrow Transplant & Cellular Immunotherapy, Tampa, FL, USA.
Abstract:
Although several decades have passed since the description of myeloproliferative neoplasms (MPN), many aspects of their pathophysiology have not been elucidated. In this review, we discuss the mutational landscape of patients with essential thrombocythemia (ET), prognostic scores and salient pathology, and clinical points. We discuss also the diagnostic challenges of differentiating ET from prefibrotic MF. We then focus on post-essential thrombocythemia myelofibrosis (post-ET MF), a rare subset of MPN that is usually studied in conjunction with post-polycythemia vera MF. The transition of ET to post-ET MF is not well studied on a molecular level, and we present available data. Patients with secondary MF could benefit from allogenic hematopoietic stem cell transplantation, and we present available data focusing on post-ET MF.
Related Concept Videos
Venous Thrombosis IV: Nursing Management
Myocarditis IV: Nursing Management
Venous Thrombosis III: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Myocarditis III: Medical Management


